News und Analysen
![Novartis: Der Konzerngewinn droht zu schrumpfen](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Novartis: Der Konzerngewinn droht zu schrumpfen
Liebe Leser,
der Schweizer Pharmariese Novartis kämpft mit sinkenden Umsätzen und schließt daher nicht mehr aus, dass es im laufenden Jahr zu einem Gewinnrückgang kommen könnte.
Wie das Unternehmen mitteilte,
![Roche: Dieses Produkt ist absolut konkurrenzlos!](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Roche: Dieses Produkt ist absolut konkurrenzlos!
Lieber Leser,
die amerikanische Zulassungsbehörde FDA hat für das Krebsmedikament Tecentriq eine beschleunigte vorläufige Zulassung ausgesprochen. Damit kann Roche sehr viel früher Geld mit der Arznei verdienen
![Novartis: Trendwende verschoben?](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Novartis: Trendwende verschoben?
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1460406897164-2'); });
Lieber Leser,
seit mittlerweile einem Jahr warten die Novartis-Aktionäre vergeblich darauf, dass das Papier
![MorphoSys: Empfindliche Schlappe, aber noch kein Grund zur Panik?](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
MorphoSys: Empfindliche Schlappe, aber noch kein Grund zur Panik?
Lieber Leser,
eine weit fortgeschrittene Studie eines neuartigen Antikörpers zur Behandlung von Muskelschwäche und Muskelschwund ist gescheitert, wie MorphoSys am Donnerstag mitteilen musste.
Enttäuschung
![Morphosys: Ist jetzt die Zeit für schnelle GEWINNE?](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Morphosys: Ist jetzt die Zeit für schnelle GEWINNE?
Lieber Leser,
am Donnerstag wurde die Aufwärtsbewegung, in der sich die Aktie des Biotech-Unternehmens Morphosys seit rund zwei Monaten befindet, jäh gestoppt. Der Titel verlor bereits am Vormittag um bis
![Novartis: die Konkurrenz schläft NICHT!](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Novartis: die Konkurrenz schläft NICHT!
Lieber Leser,
verhaltener Jahresauftakt für das Schweizer Pharmaunternehmen Novartis: aufgrund zunehmender Konkurrenz auf dem Generika-Markt und einem starken US-Dollar ist es im ersten Quartal 2016 zu einem
![MorphoSys AG: Bad News sorgen für heftigen Kurseinbruch…](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
MorphoSys AG: Bad News sorgen für heftigen Kurseinbruch…
Nicht wirklich erbaulich dürfte der heutige Tag aus Sicht von MorphoSys-Aktionären sein. Denn das auf die Entwicklung von Antikörpern spezialisierte Biotech-Unternehmen hat heute einen Rückschlag....
![Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
![Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
![Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
![Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
![Lonza Appoints Wolfgang Wienand as New Chief Executive Officer](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
![Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
![Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
![Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
![Capital Markets Day 2023:
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
Capital Markets Day 2023:
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
![Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
![Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
![Board Announcement](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Board Announcement
Board Announcement
![Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
![Q1 2023 Qualitative Update: Business Performance In Line With
Full-Year Trajectory](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Q1 2023 Qualitative Update: Business Performance In Line With
Full-Year Trajectory
![Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
![Lonza Increases Straight Bond by CHF 150 Million](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lonza Increases Straight Bond by CHF 150 Million
Lonza Increases Straight Bond by CHF 150 Million
![Lonza Launches Share Buyback Program of up to CHF 2 Billion](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Launches Share Buyback Program of up to CHF 2 Billion
![Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)